Two new second-generation BIs, insulin glargine 300 units/mL (Gla-300) and insulin degludec (IDeg), with smooth action profiles and reduced risk of hypoglycaemia, have been approved recently. [3] [4] [5] In the USA, Gla-300 became available in 2015. The EDITION randomized controlled trial (RCT) programme demonstrated that the use of Gla-300 leads to glycaemic control comparable to that of insulin glargine 100 units/mL (Gla-100),
with less hypoglycaemia in a wide range of T2D patients. 6 However, in RCTs, outcomes do not always mirror those seen in the real world, and healthcare-resource utilization (HCRU) cannot be evaluated reliably.
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To minimize confounding by indication, patients were matched 1:1 on a propensity score according to baseline demographics (age, sex, race, insurance type, geographic region), clinical features (HbA1c, BMI, Charlson Comorbidity Index score, comorbidities, hypoglycaemia), treatment (baseline BI type and concomitant drug use) and HCRU characteristics (incidence of visits) (Appendix S1 in File S1).
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Adjusted odds ratios (aOR), accounting for baseline hypoglycaemia/ HCRU incidence, were calculated for incidence of hypoglycaemia and HCRU to compare risks between the 2 matched cohorts. Adjusted mean and least squares mean (LSM) differences were calculated for event rates of hypoglycaemia and HCRU in the 2 cohorts controlled for baseline hypoglycaemia/HCRU events.
| RESULTS
The final unmatched cohort included 2196 patients who switched to Gla-300, and 3837 who switched to other BIs (Appendix S2 in File S1). After propensity score matching, each cohort comprised 1819 patients with substantial aligned baseline values (Appendix S3 in File S1). Both matched cohorts were comparable in terms of sex (approximately 49% male in matched cohorts), and mean age was approximately 59.5 years. At baseline, Gla-100 was the BI in 73.0% and 71.4% of patients in the Gla-300 and other-BI cohorts, respectively.
The remainder of patients in each cohort switched from insulin detemir. In the other-BI cohort, 22.4%, 66.9% and 10.7% of patients switched to Gla-100, insulin detemir and IDeg, respectively.
At baseline, mean HbA1c was 8.95% in the Gla-300 cohort and 8.93% in the other-BI cohort, and significantly decreased to 8.43%
and 8.43%, respectively, during follow-up (P < .001 for both cohorts).
The magnitude of HbA1c changes was comparable between cohorts (−0.51% for Gla-300 vs −0.51% for other BI; P = .928) ( Figure 1A ).
Patients using Gla-300 and those using other BIs were also equally likely to reach HbA1c <7.0% (16.8% vs 18.4%, respectively; P = .223) and HbA1c <8.0% (44.0% vs 44.2%, respectively; P = .920) during follow-up (Appendix S4 in File S1).
During follow-up, significantly fewer patients using Gla-300
experienced hypoglycaemia compared to those using other BIs (incidence: 15.4% vs 18.1%, respectively; P = .015). Patients who switched to Gla-300 were 21% less likely to have hypoglycaemia compared to other BIs adjusted for baseline hypoglycaemia incidence (aOR = 0.79; P = .015). Adjusting for baseline hypoglycaemia rate, switching to Gla-300 was associated with a 19% lower hypoglycaemia event rate at 6 months' follow-up (LSM difference: −0.15 events/ PPPY; P = .041) ( Figure 1B) . A similar trend was observed for hypoglycaemia associated with hospitalization or ED visits, with patients switching to Gla-300 having 32% fewer hypoglycaemia events related to hospitalization/ED during follow-up ( Figure 1C ).
Patients switching to Gla-300 had a lower risk of hypoglycaemia- 
| DISCUSSION

Real-world studies provide information that is complementary to
RCTs and may be more generalizable and pertinent to clinicians and healthcare-delivery systems. 11 In this real-world study with wellbalanced matched cohorts, patients switching to Gla-300 reached similar HbA1c control with a lower risk of hypoglycaemia events compared with those switching to other BIs. In addition, patients using Gla-300 had a lower risk of requiring hypoglycaemia-related, diabetes-related and all-cause ED services. This lower HCRU translated to lower costs in patients using Gla-300.
This is the first real-world study examining the comparative effects of switching to Gla-300 from another BI in patients with T2D.
The results showing comparable HbA1c reduction and reduced hypoglycaemia with Gla-300 are consistent with results from the phase III EDITION RCT programme. Real-world evidence concerning switching to Gla-300 is very limited. A recent medical chart study showed that switching to Gla-300 from another BI resulted in significantly lower Adjusted mean event rate: adjusted for baseline healthcare-resource utilization event rate
